- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 295/145 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
Patent holdings for IPC class C07D 295/145
Total number of patents in this class: 112
10-year publication summary
|
7
|
7
|
10
|
8
|
11
|
6
|
7
|
6
|
8
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Corsair Pharma, Inc. | 37 |
13 |
| Novartis AG | 10262 |
9 |
| BASF SE | 21303 |
5 |
| Pharmatrophix, Inc. | 25 |
5 |
| Hoffmann-La Roche Inc. | 3793 |
3 |
| Purdue Research Foundation | 3916 |
3 |
| RespiVert Ltd. | 79 |
3 |
| Signum Dermalogix, Inc. | 12 |
3 |
| F. Hoffmann-La Roche AG | 7837 |
2 |
| Merck Patent GmbH | 5728 |
2 |
| Auckland UniServices Limited | 500 |
2 |
| The Cooper Health System | 46 |
2 |
| The Government of The United States of America AS represented by The Secretary of The Department of Health and Human Services | 145 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3001 |
2 |
| University of North Texas Health Science Center at Fort Worth | 103 |
2 |
| Gotion Inc. | 39 |
2 |
| Guide Therapeutics, LLC | 6 |
2 |
| Contemporary Amperex Technology (Hong Kong) Limited | 4015 |
2 |
| Bristol-myers Squibb Company | 4742 |
1 |
| The Regents of the University of California | 20745 |
1 |
| Other owners | 46 |